{"id":"https://openalex.org/W2913603892","doi":"https://doi.org/10.1002/cpdd.650","title":"Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety","display_name":"Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety","publication_year":2019,"publication_date":"2019-01-24","ids":{"openalex":"https://openalex.org/W2913603892","doi":"https://doi.org/10.1002/cpdd.650","mag":"2913603892","pmid":"https://pubmed.ncbi.nlm.nih.gov/30676701","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6590207"},"language":"en","primary_location":{"id":"doi:10.1002/cpdd.650","doi":"https://doi.org/10.1002/cpdd.650","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.650","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.650","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.650","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100670406","display_name":"Edward Wolfgang Lee","orcid":"https://orcid.org/0000-0003-0418-1454","observed_orcids":["https://orcid.org/0000-0003-0418-1454"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Edward Lee","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011111764","display_name":"John P. Gibbs","orcid":"https://orcid.org/0000-0001-8892-7318","observed_orcids":["https://orcid.org/0000-0001-8892-7318"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John P. Gibbs","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA","Former employee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Former employee","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089047961","display_name":"Maurice G. Emery","orcid":"https://orcid.org/0000-0002-2985-6174","observed_orcids":["https://orcid.org/0000-0002-2985-6174"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maurice G. Emery","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA","Former employee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Former employee","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072020289","display_name":"Geoffrey A. Block","orcid":"https://orcid.org/0000-0002-4646-7074","observed_orcids":["https://orcid.org/0000-0002-4646-7074"]},"institutions":[{"id":"https://openalex.org/I4210148132","display_name":"Colorado Kidney Care","ror":"https://ror.org/05556yk85","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148132"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Geoffrey Block","raw_affiliation_strings":["Denver Nephrology Research Division, Denver, CO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Denver Nephrology Research Division, Denver, CO, USA","institution_ids":["https://openalex.org/I4210148132"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086317157","display_name":"Scott M. Wasserman","orcid":"https://orcid.org/0000-0003-0634-6021","observed_orcids":["https://orcid.org/0000-0003-0634-6021"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott M. Wasserman","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111971285","display_name":"Lisa J Hamilton","orcid":"https://orcid.org/0009-0004-4493-5614","observed_orcids":["https://orcid.org/0009-0004-4493-5614"]},"institutions":[{"id":"https://openalex.org/I4210117596","display_name":"Amgen (United Kingdom)","ror":"https://ror.org/02gvvc992","country_code":"GB","type":"company","lineage":["https://openalex.org/I1320553840","https://openalex.org/I4210117596"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lisa Hamilton","raw_affiliation_strings":["Amgen Ltd., Uxbridge, United Kingdom","Former employee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Ltd., Uxbridge, United Kingdom","institution_ids":["https://openalex.org/I4210117596"]},{"raw_affiliation_string":"Former employee","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039202929","display_name":"Sreeneeranj Kasichayanula","orcid":"https://orcid.org/0000-0002-2671-8550","observed_orcids":["https://orcid.org/0000-0002-2671-8550"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sreeneeranj Kasichayanula","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA","Former employee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Former employee","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090553583","display_name":"Patrick O. Hanafin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Hanafin","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA","Former employee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Former employee","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025538949","display_name":"Ransi M. Somaratne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ransi Somaratne","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA","Former employee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Former employee","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089580323","display_name":"Ogo I. Egbuna","orcid":"https://orcid.org/0000-0003-0548-3809","observed_orcids":["https://orcid.org/0000-0003-0548-3809","https://orcid.org/0009-0009-5996-3147"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ogo Egbuna","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA, USA","Former employee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA, USA","institution_ids":["https://openalex.org/I1320553840"]},{"raw_affiliation_string":"Former employee","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5100670406"],"corresponding_institution_ids":["https://openalex.org/I1320553840"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":1.1928,"has_fulltext":true,"cited_by_count":15,"citation_normalized_percentile":{"value":0.77184886,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"8","issue":"3","first_page":"281","last_page":"289"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/evolocumab","display_name":"evolocumab","score":1.0},{"id":"https://openalex.org/keywords/pcsk9-inhibition","display_name":"PCSK9 inhibition","score":0.8159999847412109},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.9330000281333923},{"id":"https://openalex.org/keywords/end-stage-renal-disease","display_name":"end-stage renal disease","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hemodialysis","display_name":"hemodialysis","score":0.996999979019165},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9570000171661377},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.871999979019165},{"id":"https://openalex.org/keywords/ldl-cholesterol-lowering","display_name":"LDL cholesterol lowering","score":0.9869999885559082},{"id":"https://openalex.org/keywords/drug-exposure","display_name":"drug exposure","score":0.6439999938011169},{"id":"https://openalex.org/keywords/dose-adjustment","display_name":"dose adjustment","score":0.871999979019165},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7289999723434448},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4819999933242798}],"concepts":[{"id":"https://openalex.org/C2778114629","wikidata":"https://www.wikidata.org/wiki/Q15623825","display_name":"Evolocumab","level":5,"score":0.9238777756690979},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8861944079399109},{"id":"https://openalex.org/C2780948078","wikidata":"https://www.wikidata.org/wiki/Q21130010","display_name":"PCSK9","level":5,"score":0.7298158407211304},{"id":"https://openalex.org/C159641895","wikidata":"https://www.wikidata.org/wiki/Q108377937","display_name":"Renal function","level":2,"score":0.7039681673049927},{"id":"https://openalex.org/C2778063415","wikidata":"https://www.wikidata.org/wiki/Q391744","display_name":"Hemodialysis","level":2,"score":0.6871240139007568},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6146352887153625},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.5457136631011963},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5324445962905884},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.4865831136703491},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.48238030076026917},{"id":"https://openalex.org/C2780306776","wikidata":"https://www.wikidata.org/wiki/Q426660","display_name":"Creatinine","level":2,"score":0.4387887120246887},{"id":"https://openalex.org/C3019040382","wikidata":"https://www.wikidata.org/wiki/Q476921","display_name":"End stage renal disease","level":3,"score":0.41426095366477966},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.40523311495780945},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3510426878929138},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3252779543399811},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.20152196288108826},{"id":"https://openalex.org/C2780072125","wikidata":"https://www.wikidata.org/wiki/Q28350","display_name":"Lipoprotein","level":3,"score":0.1793624758720398},{"id":"https://openalex.org/C2780745583","wikidata":"https://www.wikidata.org/wiki/Q1316030","display_name":"Apolipoprotein A1","level":4,"score":0.0},{"id":"https://openalex.org/C43554185","wikidata":"https://www.wikidata.org/wiki/Q425649","display_name":"LDL receptor","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000071449","descriptor_name":"Proprotein Convertase 9","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000091362","descriptor_name":"PCSK9 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000924","descriptor_name":"Anticholesteremic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003404","descriptor_name":"Creatinine","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005919","descriptor_name":"Glomerular Filtration Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006435","descriptor_name":"Renal Dialysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007668","descriptor_name":"Kidney","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D007668","descriptor_name":"Kidney","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D007676","descriptor_name":"Kidney Failure, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008078","descriptor_name":"Cholesterol, LDL","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011485","descriptor_name":"Protein Binding","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":5,"locations":[{"id":"doi:10.1002/cpdd.650","doi":"https://doi.org/10.1002/cpdd.650","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.650","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.650","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5578550","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6590207","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6590207","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6590207","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clin Pharmacol Drug Dev","raw_type":"Text"},{"id":"pmid:30676701","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30676701","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology in drug development","raw_type":"Clinical Study"},{"id":"pmh:oai:escholarship.org:ark:/13030/qt2dn8p61t","doi":null,"is_oa":true,"landing_page_url":"https://escholarship.org/uc/item/2dn8p61t","pdf_url":null,"source":{"id":"https://openalex.org/S4306400115","display_name":"eScholarship (California Digital Library)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2801248553","host_organization_name":"California Digital Library","host_organization_lineage":["https://openalex.org/I2801248553"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Clinical Pharmacology in Drug Development, vol 8, iss 3","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/cpdd.650","doi":"https://doi.org/10.1002/cpdd.650","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cpdd.650","pdf_url":"https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cpdd.650","source":{"id":"https://openalex.org/S2764863641","display_name":"Clinical Pharmacology in Drug Development","issn_l":"2160-763X","issn":["2160-763X","2160-7648"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology in Drug Development","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2913603892.pdf","grobid_xml":"https://content.openalex.org/works/W2913603892.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W161816689","https://openalex.org/W1593588070","https://openalex.org/W1992936536","https://openalex.org/W2016063327","https://openalex.org/W2045478673","https://openalex.org/W2067933166","https://openalex.org/W2073742622","https://openalex.org/W2086942972","https://openalex.org/W2108956796","https://openalex.org/W2121581403","https://openalex.org/W2134392564","https://openalex.org/W2155259933","https://openalex.org/W2330008904","https://openalex.org/W2523797390","https://openalex.org/W2550315736","https://openalex.org/W4298011425","https://openalex.org/W6820331027"],"related_works":["https://openalex.org/W6929479051","https://openalex.org/W7160871889","https://openalex.org/W2949589992","https://openalex.org/W4220691513","https://openalex.org/W2981843039","https://openalex.org/W2801075353","https://openalex.org/W3137484214","https://openalex.org/W1485772655","https://openalex.org/W7155556527","https://openalex.org/W2337007159"],"abstract_inverted_index":{"Abstract":[0],"We":[1],"evaluated":[2],"the":[3,80,86,97,106,117,149,155,176,239],"pharmacokinetics,":[4],"pharmacodynamics,":[5],"and":[6,73,85,93,100,133,166,183,212,219,229],"safety":[7],"of":[8,60,64,116,189,241],"evolocumab,":[9,182],"a":[10,56],"fully":[11],"human":[12],"monoclonal":[13],"antibody":[14],"against":[15],"proprotein":[16],"convertase":[17],"subtilisin":[18],"kexin":[19],"type":[20],"9":[21],"(PCSK9),":[22],"in":[23,28,79,96,148,205,214,246],"an":[24],"open\u2010label,":[25],"parallel\u2010design":[26],"study":[27],"participants":[29],"with":[30,105,154,216,223,225],"normal":[31,81,107,118,156,226],"renal":[32,38,46,82,108,119,157,227],"function":[33,83,109,120,158],"(n":[34,51],"=":[35,42,52,127,131],"6),":[36,43],"severe":[37,98,217,250],"impairment":[39],"(RI;":[40],"n":[41],"or":[44,196,252],"end\u2010stage":[45],"disease":[47],"(ESRD)":[48],"receiving":[49],"hemodialysis":[50,102,221],"6)":[53],"who":[54,248],"received":[55],"single":[57],"140\u2010mg":[58],"dose":[59,244],"evolocumab.":[61],"The":[62],"effects":[63,192,231],"evolocumab":[65,206,242],"treatment":[66],"on":[67,193],"low\u2010density":[68],"lipoprotein":[69],"cholesterol":[70],"(LDL\u2010C)":[71],"lowering":[72],"unbound":[74],"PCSK9":[75],"concentrations":[76],"were":[77,111,162,185,201,232],"similar":[78,233],"group":[84,110,121],"renally":[87,150],"impaired":[88,151],"groups.":[89,235],"Geometric":[90],"mean":[91],"Cmax":[92,211],"AUClast":[94],"values":[95],"RI":[99,218,251],"ESRD":[101,220],"groups":[103,152],"compared":[104,153,222],"lower":[112],"but":[113],"within":[114,134],"37%":[115],"(Jonckheere\u2010Terpstra":[122],"trend":[123],"test;":[124],"Cmax,":[125],"P":[126,130],".23;":[128],"AUClast,":[129,213],".22)":[132],"26%":[135],"after":[136],"adjusting":[137],"for":[138],"body":[139,142],"weight":[140,143],"(mean":[141],"was":[144,173],"approximately":[145],"9%":[146],"higher":[147],"group).":[159],"No":[160,170],"correlations":[161],"observed":[163],"between":[164],"exposure":[165],"baseline":[167],"creatinine":[168],"clearance.":[169],"adverse":[171],"event":[172],"determined":[174],"by":[175,210],"investigators":[177],"to":[178,181],"be":[179],"related":[180],"there":[184,200],"no":[186,202],"trends":[187],"indicative":[188],"clinically":[190],"important":[191],"laboratory":[194],"variables":[195],"vital":[197],"signs.":[198],"Overall,":[199],"meaningful":[203],"differences":[204],"exposure,":[207],"as":[208],"assessed":[209],"patients":[215,224,247],"function,":[228],"LDL\u2010C\u2010lowering":[230],"across":[234],"These":[236],"results":[237],"support":[238],"use":[240],"without":[243],"adjustment":[245],"have":[249],"ESRD.":[253]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2019-02-21T00:00:00"}